



### Medicines Formulary and NICE Guidance.

The Christie NHS Foundation Trust is committed to giving all its patients access to the most up-to-date treatments available.

Details of the medicines and drug regimens commonly used at The Christie are available on this website by clicking on the Patient Information, Chemotherapy Information Sheets tab.

<http://www.christie.nhs.uk/patients-and-visitors/your-treatment-and-care/patient-information/patient-booklets/chemotherapy-information-sheets/>

The management of cancer is complex, with new treatments becoming available all the time. The Trust will make every effort to ensure that these information sheets are reflective of the Drugs currently used in the Trust. If further information is required about a particular drug, or drug regimen, then please contact the pharmacy department.

The hospital has a Drugs and Therapeutics Committee which meets monthly. This committee reviews applications for new drugs treatments, and also reviews applications for using existing drugs differently.

The committee reviews all NICE guidance and Technology Appraisals pertaining to medicines.

For Technology Appraisals which give a positive assessment to new drugs, used in the management and treatment of cancer, these will be added to the hospitals drug formulary, without the need for a further application or evidence to be submitted. This usually occurs within 2 months of the publication of the NICE guidance being issued. All drugs given a positive Technology Appraisal will be available for use in the hospital within 3 months of the guidance being issued.

The Clinical Research and Effectiveness Committee of the Trust reviews all NICE guidance and monitors Trust compliance to all issued guidance.

A summary of the Trusts position with respect to NICE guidance is listed below.

The Director of Pharmacy and the pharmacy team are happy to provide further information regarding the use of medicines.

Rob Duncombe. March 2016  
Director of Pharmacy.

Contact Details.

Direct tel: 0161 446 8346

Email: Robert.duncombe@christie.nhs.uk

**Status of NICE Guidance.**  
**To March 2016**

Year / Month of publication	Type / Number	Full Name/Detail	Christie response	NICE Link
2016/01	TA378	Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy [TA378]	Compliant	<a href="#">Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy</a>
2016/01	TA381	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy [TA381]	Compliant	<a href="#">Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy</a>
2016/01	TA377	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated [TA377]	Compliant	<a href="#">Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated</a>
2016/01	TA376	Radium-223 dichloride for treating hormone-relapsed prostate	Compliant	<a href="#">Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases</a>

		cancer with bone metastases [TA376]		
2016/01	TA379	Nintedanib for treating idiopathic pulmonary fibrosis [TA379]	Response not yet available	<a href="#">Nintedanib for treating idiopathic pulmonary fibrosis</a>
2016/01	TA380	Panobinostat for treating multiple myeloma after at least 2 previous treatments [TA380]	Compliant	<a href="#">Panobinostat for treating multiple myeloma after at least 2 previous treatments</a>
2016/01	TA382	Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) [TA382]	Response not yet available	<a href="#">Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)</a>
2016/01	TA375	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [TA375]	Response not yet available	<a href="#">Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed</a>
2015/12	TA373	Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic	Compliant	<a href="#">Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis</a>

		arthritis [TA373]		
2015/12	TA372	Apremilast for treating active psoriatic arthritis [TA372]	Compliant	<a href="#">Apremilast for treating active psoriatic arthritis</a>
2015/12	TA371	Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane [TA371]	Compliant	<a href="#">Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane</a>
2015/12	TA370	Bortezomib for previously untreated mantle cell lymphoma [TA370]	Compliant	<a href="#">Bortezomib for previously untreated mantle cell lymphoma</a>
2015/12	TA369	Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears [TA369]	Compliant	<a href="#">Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears</a>
2015/12	HST2	Elosulfase alfa for treating mucopolysaccharidosis type IVa [HST2]	Not carried out at the Christie	<a href="#">Elosulfase alfa for treating mucopolysaccharidosis type IVa</a>
2015/12	TA374	Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy [TA374]	Compliant	<a href="#">Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy</a>

2015/11	TA363	Ledipasvir–sofosbuvir for treating chronic hepatitis C [TA363]	Compliant	<a href="#">Ledipasvir–sofosbuvir for treating chronic hepatitis C</a>
2015/11	TA364	Daclatasvir for treating chronic hepatitis C [TA364]	Compliant	<a href="#">Daclatasvir for treating chronic hepatitis C</a>
2015/11	TA367	Vortioxetine for treating major depressive episodes [TA367]	Compliant	<a href="#">Vortioxetine for treating major depressive episodes</a>
2015/11	TA368	Apremilast for treating moderate to severe plaque psoriasis [TA368]	Compliant	<a href="#">Apremilast for treating moderate to severe plaque psoriasis</a>
2015/11	TA366	Pembrolizumab for advanced melanoma not previously treated with ipilimumab [TA366]	Compliant	<a href="#">Pembrolizumab for advanced melanoma not previously treated with ipilimumab</a>
2015/11	TA365	Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C [TA365]	Compliant	<a href="#">Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C</a>
2015/10	TA360	Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer TA360	Not carried out at the Christie	<a href="#">Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer</a>
2015/10	TA357	Pembrolizumab for treating	Compliant	<a href="#">Pembrolizumab for treating advanced melanoma after disease progression with</a>

		advanced melanoma after disease progression with ipilimumab [TA357]		<a href="#">ipilimumab</a>
2015/10	HTTA325	Nalmefene [HTTA325]	Compliant	<a href="#">Nalmefene</a>
2015/10	TA361	Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) [TA361]	Terminated appraisal (by issuing body)	<a href="#">Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)</a>
2015/10	TA359	Idelalisib for treating chronic lymphocytic leukaemia [TA359]	Compliant	<a href="#">Idelalisib for treating chronic lymphocytic leukaemia</a>
2015/10	TA358	Tolvaptan for treating autosomal dominant polycystic kidney disease [TA358]	Compliant	<a href="#">Tolvaptan for treating autosomal dominant polycystic kidney disease</a>
2015/10	TA362	Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) [TA362]	Terminated appraisal (by issuing body)	<a href="#">Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)</a>
2015/09	TA356	Ruxolitinib for treating polycythaemia vera (terminated appraisal) [TA356]	Terminated appraisal (by issuing body)	<a href="#">Ruxolitinib for treating polycythaemia vera (terminated appraisal)</a>

2015/09	TA355	Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation [TA355]	Compliant	<a href="#">Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation</a>
2015/08	TA354	Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism [TA354]	Compliant	<a href="#">Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism</a>
2015/08	TA353	Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) [TA353]	Terminated appraisal (by issuing body)	<a href="#">Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)</a>
2015/08	TA352	Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy [TA352]	Compliant	<a href="#">Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy</a>
2015/07	TA345	Naloxegol for treating opioid-induced constipation [TA345]	Compliant	<a href="#">Naloxegol for treating opioid-induced constipation</a>
2015/07	TA351	Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring	Not carried out at the Christie	<a href="#">Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)</a>

		interruption of anti-platelet therapy (terminated appraisal) [TA351]		
2015/07	TA349	Dexamethasone intravitreal implant for treating diabetic macular oedema [TA349]	Not carried out at the Christie	<a href="#">Dexamethasone intravitreal implant for treating diabetic macular oedema</a>
2015/07	TA350	Secukinumab for treating moderate to severe plaque psoriasis [TA350]	Compliant	<a href="#">Secukinumab for treating moderate to severe plaque psoriasis</a>
2015/07	TA348	Everolimus for preventing organ rejection in liver transplantation TA348	Not carried out at the Christie	<a href="#">Everolimus for preventing organ rejection in liver transplantation</a>
2015/07	TA346	Aflibercept for treating diabetic macular oedema [TA346]	Not carried out at the Christie	<a href="#">Aflibercept for treating diabetic macular oedema</a>
2015/07	TA347	Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer [TA347]	Compliant	<a href="#">Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer</a>
2015/07	HTTA329	Introducing biosimilar versions of infliximab: Inflectra and Remsima [HTTA329]	Not carried out at the Christie	<a href="#">Introducing biosimilar versions of infliximab: Inflectra and Remsima</a>
2015/06	TA341	Apixaban for the treatment and secondary	Compliant	<a href="#">Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism   Guidance and</a>

		prevention of deep vein thrombosis and/or pulmonary embolism [TA341]		<a href="#">guidelines   NICE</a>
2015/06	TA342	Vedolizumab for treating moderately to severely active ulcerative colitis [TA342]	Compliant	<a href="#">Vedolizumab for treating moderately to severely active ulcerative colitis   Guidance and guidelines   NICE</a>
2015/06	TA339	Omalizumab for previously treated chronic spontaneous urticaria [TA339]	Compliant	<a href="#">Omalizumab for previously treated chronic spontaneous urticaria   Guidance and guidelines   NICE</a>
2015/06	TA344	Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia TA344	Compliant	<a href="#">Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia</a>
2015/06	TA343	Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia TA343	Compliant	<a href="#">Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia</a>
2015/06	TA340	Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) [TA340]	Compliant	<a href="#">Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313)   Guidance and guidelines   NICE</a>
2015/03	TA335	Rivaroxaban for preventing adverse outcomes after acute management of acute coronary	Compliant	<a href="#">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome</a>

		syndrome		
2015/03	TA338	Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib	Compliant	<a href="#">Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib</a>
2015/03	TA336	Empagliflozin in combination therapy for treating type 2 diabetes	Compliant	<a href="#">Empagliflozin in combination therapy for treating type 2 diabetes</a>
2015/03	TA337	Rifaximin for preventing episodes of overt hepatic encephalopathy	Compliant	<a href="#">Rifaximin for preventing episodes of overt hepatic encephalopathy</a>
2015/02	TA332	Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer [TA332]	Not carried out at the Christie	<a href="#">Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer</a>
2015/02	TA331	Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C [TA331]	Not carried out at the Christie	<a href="#">Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C</a>
2015/02	TA333	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment	Compliant	<a href="#">Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment</a>

		[TA333]		
2015/02	TA334	Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) [TA334]	Terminated appraisal (by issuing body)	<a href="#">Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)</a>
2015/02	TA329	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [TA329]	Not carried out at the Christie	<a href="#">Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)</a>
2015/02	TA330	Sofosbuvir for treating chronic hepatitis C (TA330)	Not carried out at the Christie	<a href="#">Sofosbuvir for treating chronic hepatitis C</a>
2015/01	HST1	Eculizumab for treating atypical haemolytic uraemic syndrome [HST1]	Compliant	<a href="#">Eculizumab for treating atypical haemolytic uraemic syndrome</a>
2014/12	TA328	Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) TA328	Terminated appraisal (by issuing body)	<a href="#">Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)</a>
2014/12	TA327	Dabigatran etexilate for the treatment and secondary prevention of deep vein	Compliant	<a href="#">Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism</a>

		thrombosis and/or pulmonary embolism TA327		
2014/11	TA323	Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142) [TA323]	Compliant	<a href="#">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)</a>
2014/11	TA324	Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88)	Not carried out at the Christie	<a href="#">Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88)</a>
2014/11	TA325	Nalmefene for reducing alcohol consumption in people with alcohol dependence [TA325]	Compliant	<a href="#">Nalmefene for reducing alcohol consumption in people with alcohol dependence</a>
2014/11	TA326	Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) [TA326]	Compliant	<a href="#">Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196)</a>
2014/10	TA321	Dabrafenib for treating	Compliant	<a href="#">Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive</a>

		unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)		<a href="#">melanoma</a>
2014/09	TA322	Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality/ TA322	Compliant	<a href="#">Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality</a>
2014/08	TA320	Dimethyl fumarate for treating relapsing - remitting multiple sclerosis [TA320]	Not carried out at the Christie	<a href="#">Dimethyl fumarate for treating relapsing-remitting multiple sclerosis</a>
2014/07	TA318	Lubiprostone for treating chronic idiopathic constipation/TA318	Not carried out at the Christie	<a href="#">Lubiprostone for treating chronic idiopathic constipation/TA318</a>
2014/07	TA317	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)/TA317	Not carried out at the Christie	<a href="#">Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)/TA317</a>
2014/07	TA316	Enzalutamide for metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing	Compliant	<a href="#">Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen/TA316</a>

		regimen/TA316		
2014/07	TA319	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma/TA319	Compliant	<a href="#">Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma/TA319</a>
2014/06	TA314	Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120)	Not carried out at the Christie	<a href="#">Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120)</a>
2014/06	TA315	Canagliflozin in combination therapy for treating type 2 diabetes	Compliant	<a href="#">Canagliflozin in combination therapy for treating type 2 diabetes</a>
2014/05	TA312	Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)	Not carried out at the Christie	<a href="#">Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)</a>
2014/04	TA309	Lung cancer (non small cell, non squamous) - pemetrexed (TA309)	Compliant	<a href="#">Lung cancer (non small cell, non squamous) - pemetrexed</a>
2014/04	TA311	Multiple myeloma - bortezomib (induction therapy) (TA311)	Compliant	<a href="#">Multiple myeloma - bortezomib (induction therapy)</a>
2014/04	TA310	Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310)	Compliant	<a href="#">Lung cancer (non small cell, EGFR mutation positive) - afatinib</a>

2014/03	TA307	Colorectal cancer (metastatic) - aflibercept (TA307)	Compliant	<a href="#">Colorectal cancer (metastatic) - aflibercept</a>
2014/03	TA308	Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)	Compliant	<a href="#">Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)</a>
2014/02	TA304	Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (TA304)	Not carried out at the Christie	<a href="#">Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44)</a>
2014/02	TA306	Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)	Compliant	<a href="#">Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy</a>
2014/02	TA305	Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)	Not carried out at the Christie	<a href="#">Macular oedema (central retinal vein occlusion) - aflibercept solution for injection</a>
2014/01	TA303	Multiple sclerosis (relapsing) - teriflunomide (TA303)	Not carried out at the Christie	<a href="#">Multiple sclerosis (relapsing) - teriflunomide</a>
2013/11	TA301	Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)	Not carried out at the Christie	<a href="#">Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271)</a>

2013/11	TA300	Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300)	Not carried out at the Christie	<a href="#">Hepatitis C (children and young people) - peginterferon alfa and ribavirin</a>
2013/11	TA299	Leukaemia (chronic myeloid) - bosutinib (TA299)	Compliant	<a href="#">Leukaemia (chronic myeloid) - bosutinib</a>
2013/11	TA298	Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)	Not carried out at the Christie	<a href="#">Choroidal neovascularisation (pathological myopia) - ranibizumab</a>
2013/11	TA302	Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) (TA302)	Terminated appraisal (by issuing body)	<a href="#">Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)</a>
2013/10	TA297	Vitreomacular traction - ocriplasmin (TA297)	Not carried out at the Christie	<a href="#">Vitreomacular traction - ocriplasmin</a>
2013/09	TA296	Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296)	Compliant	<a href="#">Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib</a>
2013/08	TA295	Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)	Compliant	<a href="#">Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)</a>

2013/07	TA292	Bipolar disorder (children) - aripiprazole (TA292)	Not carried out at the Christie	<a href="#">Bipolar disorder (children) - aripiprazole</a>
2013/07	TA294	Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)	Not carried out at the Christie	<a href="#">Macular degeneration (wet age-related) - aflibercept (1st line)</a>
2013/07	TA293	Thrombocytopenic purpura - eltrombopag (TA293)	Compliant	<a href="#">Thrombocytopenic purpura - eltrombopag</a>
2013/06	TA288	Type 2 diabetes - Dapagliflozin combination therapy (TA288)	Compliant	<a href="#">Type 2 diabetes - Dapagliflozin combination therapy</a>
2013/06	TA287	Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)	Compliant	<a href="#">Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban</a>
2013/06	TA291	Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291)	Not carried out at the Christie	<a href="#">Gout (tophaceous, severe debilitating, chronic) - pegloticase</a>
2013/06	TA290	Overactive bladder - mirabegron (TA290)	Compliant	<a href="#">Overactive bladder - mirabegron</a>
2013/06	TA289	Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289)	Compliant	<a href="#">Myelofibrosis (splenomegaly, symptoms) - ruxolitinib</a>
2013/05	TA284	Bevacizumab in combination with paclitaxel and carboplatin for first-line	Compliant Equivalent	<a href="#">Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer</a>

		treatment of advanced ovarian cancer (TA284)		
2013/05	TA283	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion	Not carried out at the Christie	<a href="#">ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-ta283</a>
2013/05	TA286	Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal) (TA286)	Not carried out at the Christie	<a href="#">Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal)</a>
2013/05	TA285	Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285)	Compliant Equivalent	<a href="#">bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinum sensitive ovarian cancer ta285</a>
2013/04	TA280	Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) (TA280)	Not carried out at the Christie	<a href="#">Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234)</a>
2013/04	TA279	Vertebral fractures - vertebroplasty and kyphoplasty (TA279)	Not carried out at the Christie	<a href="#">Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures</a>
2013/04	TA282	Idiopathic pulmonary fibrosis - pirfenidone	Not carried out at the Christie	<a href="#">Pirfenidone for treating idiopathic pulmonary fibrosis</a>

		(TA282)		
2013/04	TA278	Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)	Not carried out at the Christie	<a href="#">Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201)</a>
2013/04	TA281	Gout - canakinumab (terminated appraisal) (TA281)	Not carried out at the Christie	<a href="#">Gout - canakinumab (terminated appraisal)</a>
2013/03	TA276	Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)	Compliant	<a href="#">Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin</a>
2013/03	TA277	Methylalntrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)	Terminated appraisal (by issuing body)	<a href="#">Methylalntrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)</a>
2013/02	TA274	Macular oedema (diabetic) - ranibizumab (TA274)	Not carried out at the Christie	<a href="#">Macular oedema (diabetic) - ranibizumab (TA274)</a>
2013/02	TA275	Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)	Not carried out at the Christie	<a href="#">Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)</a>
2013/01	TA271	Diabetic macular oedema -	Not carried	<a href="#">Diabetic macular oedema - fluocinolone</a>

		fluocinolone acetonide intravitreal implant	out at the Christie	<a href="#">acetonide intravitreal implant</a>
2013/01	TA272	Urothelial tract carcinoma (transitional cell, advanced, metastatic)	Compliant	<a href="#">Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine</a>
2013/01	TA273	Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)	Not carried out at the Christie	<a href="#">Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)</a>
2012/12	TA268	Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma	Compliant	<a href="#">Melanoma (stage III or IV) - ipilimumab (TA268)</a>
2012/12	TA270	Decitabine for the treatment of acute myeloid leukaemia - terminated appraisal	Terminated appraisal (by issuing body)	<a href="#">Leukaemia (acute myeloid) - decitabine (terminated appraisal) (TA270)</a>
2012/12	TA269	Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)	Compliant	<a href="#">Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib</a>
2012/11	TA266	Cystic fibrosis - mannitol dry powder for inhalation (TA266)	Not carried out at the Christie	<a href="#">Cystic fibrosis - mannitol dry powder for inhalation (TA266)</a>
2012/11	TA267	Chronic heart failure - ivabradine (TA267)	Not carried out at the Christie	<a href="#">Chronic heart failure - ivabradine (TA267)</a>
2012/10	TA265	Denosumab for the prevention of	Compliant	<a href="#">Bone metastases from solid tumours - denosumab</a>

		skeletal-related events in adults with bone metastases from solid tumours		
2012/09	TA264	Stroke (acute, ischaemic) - alteplase (TA264)	Not carried out at the Christie	<a href="#">Stroke (Acute, Ischaemic) - alteplase TA264</a>
2012/08	TA263	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)	Compliant	<a href="#">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer</a>
2012/07	TA261	Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)	Compliant	<a href="#">Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban</a>
2012/07	TA262	Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) (TA262)	Not carried out at the Christie	<a href="#">Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)</a>
2012/06	TA258	Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)	Compliant	<a href="#">Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)</a>
2012/06	TA260	Migraine (chronic) - botulinum toxin type A	Not carried out at the Christie	<a href="#">Migraine (chronic) - botulinum toxin type A</a>
2012/06	TA259	Prostate cancer (metastatic, castration resistant) -	Compliant	<a href="#">Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy)</a>

		abiraterone (following cytotoxic therapy)		
2012/06	TA257	Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)	Compliant	<a href="#">Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)</a>
2012/05	TA256	Atrial fibrillation (stroke prevention) - rivaroxaban	Not carried out at the Christie	<a href="#">Atrial fibrillation (stroke prevention) - rivaroxaban</a>
2012/05	TA255	Prostate cancer - cabazitaxel	Compliant	<a href="#">Prostate cancer - cabazitaxel</a>
2012/04	TA253	Hepatitis C (genotype 1) - boceprevir	Not carried out at the Christie	<a href="#">Hepatitis C (genotype 1) - boceprevir</a>
2012/04	TA250	Breast cancer (advanced) - eribulin	Compliant	<a href="#">Breast cancer (advanced) - eribulin</a>
2012/04	TA251	Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib	Compliant	<a href="#">Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib</a>
2012/04	TA254	Multiple sclerosis (relapsing-remitting) - fingolimod	Not carried out at the Christie	<a href="#">Multiple sclerosis (relapsing-remitting) - fingolimod</a>
2012/04	TA252	Hepatitis C (genotype 1) - telaprevir	Not carried out at the Christie	<a href="#">Hepatitis C (genotype 1) - telaprevir</a>
2012/03	TA249	Atrial fibrillation - dabigatran etexilate	Not carried out at the Christie	<a href="#">Atrial fibrillation - dabigatran etexilate</a>

2012/02	TA246	Venom anaphylaxis - immunotherapy pharmlagen	Not carried out at the Christie	<a href="#">Venom anaphylaxis - immunotherapy pharmlagen</a>
2012/02	TA248	Diabetes (type 2) - exenatide (prolonged release)	Not carried out at the Christie	<a href="#">Diabetes (type 2) - exenatide (prolonged release)</a>
2012/02	TA247	Rheumatoid arthritis - tocilizumab (rapid review TA198)	Not carried out at the Christie	<a href="#">Rheumatoid arthritis - tocilizumab (rapid review TA198)</a>
2012/01	TA244	Chronic obstructive pulmonary disease - roflumilast	Not carried out at the Christie	<a href="#">Chronic obstructive pulmonary disease - roflumilast</a>
2012/01	TA242	Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review of TA150 & partial review of TA118) Not recommended	Compliant	<a href="#">Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)</a>
2012/01	TA241	Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) Partial review of TA70	Compliant	<a href="#">Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)</a>
2012/01	TA243	Follicular lymphoma, rituximab Review of TA110	Compliant	<a href="#">Follicular lymphoma - rituximab (review)</a>
2012/01	TA245	Venous thromboembolism - apixaban (hip and knee surgery)	Not carried out at the Christie	<a href="#">Venous thromboembolism - apixaban (hip and knee surgery)</a>
2011/12	TA240	Colorectal cancer (metastatic) -	Compliant	<a href="#">Colorectal cancer (metastatic) - panitumumab</a>

		panitumumab		
2011/12	TA238	Arthritis (juvenile idiopathic, systemic) - tocilizumab	Not carried out at the Christie	<a href="#">Arthritis (juvenile idiopathic, systemic) - tocilizumab</a>
2011/12	TA239	Breast cancer (metastatic) - fulvestrant	Compliant	<a href="#">Breast cancer (metastatic) - fulvestrant</a>
2011/10	TA235	Osteosarcoma - mifamurtide	Compliant	<a href="#">Osteosarcoma - mifamurtide</a>
2011/10	TA236	Acute coronary syndromes - ticagrelor	Not carried out at the Christie	<a href="#">Acute coronary syndromes - ticagrelor</a>
2011/08	TA234	Rheumatoid arthritis - abatacept (2nd line)	Not carried out at the Christie	<a href="#">Rheumatoid arthritis - abatacept (2nd line)</a>
2011/08	TA233	Ankylosing spondylitis - golimumab	Not carried out at the Christie	<a href="#">Ankylosing spondylitis - golimumab</a>
2011/07	TA228	Multiple myeloma (first line) - bortezomib and thalidomide	Compliant	<a href="#">Multiple myeloma (first line) - bortezomib and thalidomide</a>
2011/07	TA230	Myocardial infarction (persistent ST-segment elevation) - bivalirudin	Not carried out at the Christie	<a href="#">Myocardial infarction (persistent ST-segment elevation) - bivalirudin</a>
2011/07	TA231	Depression - agomelatine (terminated appraisal)	Not carried out at the Christie	<a href="#">Depression - agomelatine (terminated appraisal)</a>
2011/07	TA229	Macular oedema (retinal vein occlusion) - dexamethasone	Not carried out at the Christie	<a href="#">Macular oedema (retinal vein occlusion) - dexamethasone</a>
2011/07	TA232	Epilepsy (partial) - retigabine	Not carried	<a href="#">Epilepsy (partial) - retigabine (adjuvant)</a>

		(adjuvant)	out at the Christie	
2011/06	TA224	Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal)	Not carried out at the Christie	<a href="#">Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal)</a>
2011/06	TA225	Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab	Not carried out at the Christie	<a href="#">Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab</a>
2011/06	TA226	Lymphoma (follicular non-Hodgkin's) - rituximab	Compliant	<a href="#">Lymphoma (follicular non-Hodgkin's) - rituximab</a>
2011/05	TA223	Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate	Not carried out at the Christie	<a href="#">Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate</a>
2011/04	TA219	Everolimus for the second-line treatment of advanced renal cell carcinoma	Compliant	<a href="#">Everolimus for the second-line treatment of advanced renal cell carcinoma</a>
2011/04	TA220	Psoriatic arthritis - golimumab	Not carried out at the Christie	<a href="#">Psoriatic arthritis - golimumab</a>
2011/04	TA222	Trabectedin for the treatment of relapsed ovarian cancer	Compliant	<a href="#">Ovarian cancer (relapsed) - trabectedin</a>
2011/04	TA221	Romiplostim for the treatment of chronic immune or idiopathic thrombocytopeni	Compliant	<a href="#">Thrombocytopenic purpura - romiplostim</a>

		c purpura		
2011/03	TA217	Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine	Not carried out at the Christie	<a href="#">Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine</a>
2011/03	TA218	Myelodysplastic syndromes - azacitidine	Compliant	<a href="#">Myelodysplastic syndromes - azacitidine</a>
2011/02	TA215	Pazopanib for the first line treatment of metastatic renal cell carcinoma	Compliant	<a href="#">Renal cell carcinoma (first line metastatic) - pazopanib</a>
2011/02	TA214	Breast cancer - bevacizumab (in combination with a taxane)	Compliant	<a href="#">Breast cancer - bevacizumab (in combination with a taxane)</a>
2011/02	TA216	Bendamustine for the treatment of chronic lymphocytic leukaemia	Compliant	<a href="#">Leukaemia (lymphocytic) - bendamustine</a>
2011/01	TA213	Aripiprazole for schizophrenia in people aged 15 to 17 years	Not carried out at the Christie	<a href="#">Schizophrenia - aripiprazole</a>
2011/01	TA160	Osteoporosis - primary prevention	Not carried out at the Christie	<a href="#">Osteoporosis - primary prevention</a>
2011/01	TA161	Osteoporosis - secondary prevention including strontium ranelate	Not carried out at the Christie	<a href="#">Osteoporosis - secondary prevention including strontium ranelate</a>
2010/12	TA210	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular	Not carried out at the Christie	<a href="#">Vascular disease - clopidogrel and dipyridamole</a>

		events (review of technology appraisal guidance 90)		
2010/12	TA212	Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer	Compliant	<a href="#">Colorectal cancer (metastatic) - bevacizumab</a>
2010/12	TA211	Constipation (women) - prucalopride	Not carried out at the Christie	<a href="#">Constipation (women) - prucalopride</a>
2010/11	TA209	Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (Part review of TA86)	Compliant	<a href="#">Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib</a>
2010/11	TA208	Gastric cancer (HER2-positive metastatic) - trastuzumab	Compliant	<a href="#">Gastric cancer (HER2-positive metastatic) - trastuzumab</a>
2010/10	TA203	Diabetes (type 2) - liraglutide	Not carried out at the Christie	<a href="#">Diabetes (type 2) - liraglutide</a>
2010/10	TA201	Asthma (in children) - omalizumab	Not carried out at the Christie	<a href="#">Asthma (in children) - omalizumab</a>
2010/10	TA204	Osteoporotic fractures - denosumab	Not carried out at the Christie	<a href="#">Osteoporotic fractures - denosumab</a>
2010/10	TA207	Mantle cell lymphoma (relapsed) - temsirolimus	Compliant	<a href="#">Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)</a>

		(terminated appraisal)		
2010/10	TA202	Chronic lymphocytic leukaemia - ofatumumab	Compliant	<a href="#">Chronic lymphocytic leukaemia - ofatumumab</a>
2010/10	TA206	Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)	Compliant	<a href="#">Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal)</a>
2010/10	TA205	Thrombocytopenic purpura - eltrombopag	Not carried out at the Christie	<a href="#">Thrombocytopenic purpura - eltrombopag</a>
2010/09	TA200	Hepatitis C - peginterferon alfa and ribavirin	Not carried out at the Christie	<a href="#">Hepatitis C - peginterferon alfa and ribavirin</a>
2010/08	TA199	Psoriatic arthritis - etanercept, infliximab and adalimumab	Not carried out at the Christie	<a href="#">Psoriatic arthritis - etanercept, infliximab and adalimumab</a>
2010/08	TA197	Atrial fibrillation - dronedarone	Compliant	<a href="#">Atrial fibrillation - dronedarone</a>
2010/08	TA198	Tocilizumab for rheumatoid arthritis	Not carried out at the Christie	<a href="#">Rheumatoid arthritis - tocilizumab</a>
2010/08	TA195	Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor	Not carried out at the Christie	<a href="#">Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor</a>
2010/07	TA193	Rituximab for the treatment of relapsed chronic lymphocytic	Compliant Equivalent	<a href="#">Leukaemia (chronic lymphocytic, relapsed) - rituximab</a>

		leukaemia		
2010/07	TA191	Capecitabine for the treatment of advanced gastric cancer	Compliant	<a href="#">Gastric cancer (advanced) - capecitabine</a>
2010/07	TA192	Lung cancer (non-small-cell, first line) - gefitinib	Compliant	<a href="#">Lung cancer (non-small-cell, first line) - gefitinib</a>
2010/07	TA194	Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)	Compliant	<a href="#">Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)</a>
2010/06	TA190	Lung cancer (non-small-cell) - pemetrexed (maintenance)	Not carried out at the Christie	<a href="#">Lung cancer (non-small-cell) - pemetrexed (maintenance)</a>
2010/05	TA187	Crohn's disease - infliximab (review) and adalimumab (review of TA40) Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab, and infliximab [review]) for Crohn's disease (review of TA40)	Not carried out at the Christie	<a href="#">Crohn's disease - infliximab (review) and adalimumab (review of TA40)</a>
2010/05	TA189	Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)	Compliant	<a href="#">Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)</a>
2010/05	TA188	Human growth hormone (somatropin) for the treatment of growth failure in	Not carried out at the Christie	<a href="#">Human growth hormone (somatropin) for the treatment of growth failure in children (review)</a>

		children (review)		
2010/02	TA185	Soft tissue sarcoma - trabectedin	Compliant	<a href="#">Soft tissue sarcoma - trabectedin</a>
2010/02	TA186	Certolizumab pegol for the treatment of rheumatoid arthritis	Not carried out at the Christie	<a href="#">Rheumatoid arthritis - certolizumab pegol</a>
2009/11	TA184	Topotecan for the treatment of relapsed small-cell lung cancer	Compliant	<a href="#">Lung cancer (small-cell) - topotecan</a>
2009/10	TA183	Topotecan for the treatment of recurrent carcinoma of the cervix	compliant	<a href="#">Cervical cancer (recurrent) - topotecan</a>
2009/09	TA181	Pemetrexed for the first-line treatment of non-small-cell lung cancer	Compliant	<a href="#">Lung cancer (non-small cell, first line treatment) - pemetrexed</a>
2009/09	TA179	Sunitinib for the treatment of gastrointestinal stromal tumours	Compliant	<a href="#">Gastrointestinal stromal tumours - sunitinib</a>
2009/09	TA180	Ustekinumab for the treatment of adults with moderate to severe psoriasis	Not carried out at the Christie	<a href="#">Psoriasis - ustekinumab</a>
2009/08	TA177	Alitretinoin for the treatment of severe chronic hand eczema	Not carried out at the Christie	<a href="#">Eczema (chronic) - alitretinoin</a>
2009/08	TA178	Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus	Compliant	<a href="#">Renal cell carcinoma</a>

		(first-line) for the treatment of advanced and/or metastatic renal cell carcinoma		
2009/08	TA176	Cetuximab for the first line treatment of metastatic colorectal cancer	Compliant	<a href="#">Colorectal cancer (first line) - cetuximab</a>
2009/07	TA174	Rituximab for first line treatment of chronic lymphocytic leukaemia	Compliant	<a href="#">Leukaemia (chronic lymphocytic, first line) - rituximab</a>
2009/07	TA173	Tenofovir disoproxil fumarate for the treatment of hepatitis B	Not carried out at the Christie	<a href="#">Hepatitis B - tenofovir disoproxil fumarate</a>
2009/06	TA171	Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy	Compliant	<a href="#">Multiple myeloma - lenalidomide</a>
2009/06	TA172	Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck	Compliant	<a href="#">Head and neck cancer (squamous cell carcinoma) - cetuximab</a>
2009/04	TA170	Rivaroxaban for the prevention of venous thromboembolism	Not carried out at the Christie	<a href="#">Venous thromboembolism - rivaroxaban</a>
2009/03	TA169	Sunitinib for the first-line treatment of advanced and/or metastatic renal	Compliant	<a href="#">Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma</a>

		cell carcinoma		
2009/02	TA168	Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)	Not carried out at the Christie	<a href="#">Influenza - zanamivir, amantadine and oseltamivir (review)</a>
2009/02	TA167	Endovascular stent - grafts for the treatment of abdominal aortic aneurysms	Not carried out at the Christie	<a href="#">Abdominal aortic aneurysm - endovascular stent-grafts</a>
2009/01	TA165	Machine perfusion systems and cold static storage of kidneys from deceased donors	Not carried out at the Christie	<a href="#">Organ preservation (renal) - machine perfusion and static storage</a>
2009/01	TA166	Cochlear implants for severe to profound deafness in children and adults	Not carried out at the Christie	<a href="#">Hearing impairment - cochlear implants</a>
2008/12	TA164	Febuxostat for the management of hyperuricaemia in people with gout	Not carried out at the Christie	<a href="#">Hyperuricaemia - febuxostat</a>
2008/12	TA163	Infliximab for the treatment of acute exacerbations of ulcerative colitis	Not carried out at the Christie	<a href="#">Ulcerative colitis (acute exacerbations) - infliximab</a>
2008/11	TA162	Erlotinib for the treatment of non-small cell lung cancer	Compliant	<a href="#">Lung cancer (non-small-cell) - erlotinib</a>
2008/11	TA160	Osteoporosis - primary prevention	Not carried out at the Christie	<a href="#">Osteoporosis - primary prevention</a>

2008/11	TA161	Osteoporosis - secondary prevention including strontium ranelate	Not carried out at the Christie	<a href="#">Osteoporosis - secondary prevention including strontium ranelate</a>
2008/10	TA159	Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin	Not carried out at the Christie	<a href="#">Pain (chronic neuropathic or ischaemic) - spinal cord stimulation</a>
2008/09	TA157	Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults	Not carried out at the Christie	<a href="#">Venous thromboembolism - dabigatran</a>
2008/09	TA158	Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of TA67)	Compliant	<a href="#">Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir</a>
2008/08	TA156	Pregnancy - routine anti-D prophylaxis for rhesus negative women (review of TA41)	Not carried out at the Christie	<a href="#">Pregnancy (rhesus negative women) - routine anti-D (review)</a>
2008/08	TA154	Telbivudine for the treatment of chronic hepatitis B	Not carried out at the Christie	<a href="#">Hepatitis B - telbivudine</a>
2008/08	TA153	Entecavir for the treatment of chronic hepatitis B	Not carried out at the Christie	<a href="#">Hepatitis B - entecavir</a>
2008/08	TA155	Pegaptanib and ranibizumab for the treatment of age-related	Not carried out at the	<a href="#">Macular degeneration (age-related) - ranibizumab and pegaptanib</a>

		macular degeneration	Christie	
2008/07	TA151	Continuous subcutaneous insulin infusion for the treatment of diabetes (review TA 57)	Not carried out at the Christie	<a href="#">Diabetes - insulin pump therapy</a>
2008/07	TA152	Drug-eluting stents for the treatment of coronary artery disease	Not carried out at the Christie	<a href="#">Coronary artery disease - drug-eluting stents</a>
2008/06	TA150	Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (terminated appraisal)	Compliant	<a href="#">Colorectal cancer (metastatic) - cetuximab (terminated appraisal)</a>
2008/06	TA144	Rimonabant for the treatment of overweight and obese patients	Not carried out at the Christie	<a href="#">Obesity - rimonabant</a>
2008/06	TA146	Adalimumab for the treatment of psoriasis	Not carried out at the Christie	<a href="#">Psoriasis - adalimumab</a>
2008/06	TA148	Bevacizumab for the treatment of non-small-cell lung cancer	Compliant	<a href="#">Lung cancer (non-small-cell) - bevacizumab (terminated appraisal)</a>
2008/06	TA147	Bevacizumab for the first-line treatment of metastatic breast cancer (terminated appraisal)	Compliant	<a href="#">Breast cancer (advanced &amp; metastatic) - bevacizumab (terminated appraisal)</a>
2008/06	TA145	Cetuximab for the treatment of	Compliant	<a href="#">Head and neck cancer - cetuximab</a>

		head and neck cancer		
2008/06	TA149	Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)	Compliant	<a href="#">Glioma (recurrent) - carmustine implants (terminated appraisal)</a>
2008/05	TA143	Adalimumab, etanercept and infliximab for ankylosing spondylitis	Not carried out at the Christie	<a href="#">Ankylosing spondylitis - adalimumab, etanercept and infliximab</a>
2008/04	TA141	Abatacept for the treatment of rheumatoid arthritis	Not carried out at the Christie	<a href="#">Rheumatoid arthritis (refractory) - abatacept</a>
2008/04	TA140	Infliximab for the sub-acute manifestations of ulcerative colitis	Not carried out at the Christie	<a href="#">Colitis (ulcerative) - infliximab</a>
2008/03	TA139	Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome	Not carried out at the Christie	<a href="#">Sleep apnoea - continuous positive airways pressure (CPAP)</a>
2008/03	TA138	Corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over	Not carried out at the Christie	<a href="#">Asthma (in adults) - corticosteroids</a>
2008/02	TA136	Atypical psychosis (first onset) - neuro-imaging Structural neuroimaging in first episode psychosis	Not carried out at the Christie	<a href="#">Atypical psychosis (first onset) - neuro-imaging</a>

2008/02	TA137	Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)	Compliant	<a href="#">Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)</a>
2008/01	TA134	Infliximab for the treatment of psoriasis	Not carried out at the Christie	<a href="http://www.nice.org.uk/nicemedia/pdf/TA134QuickRefGuide.pdf">http://www.nice.org.uk/nicemedia/pdf/TA134QuickRefGuide.pdf</a>
2008/01	TA135	Pemetrexed disodium for the treatment of mesothelioma	Compliant	<a href="http://www.nice.org.uk/nicemedia/pdf/TA135quickrefguide.pdf">http://www.nice.org.uk/nicemedia/pdf/TA135quickrefguide.pdf</a>
2007/11	TA133	Omalizumab for severe persistent allergic asthma	Not carried out at the Christie	<a href="#">Asthma (uncontrolled) - omalizumab</a>
2007/11	TA131	Corticosteroids for the treatment of chronic asthma in children under the age of 12 years	Not carried out at the Christie	<a href="#">Asthma (in children) - corticosteroids</a>
2007/11	TA132	Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterol aemia	Not carried out at the Christie	<a href="#">Hypercholesterolemia - ezetimibe</a>
2007/10	TA129	Bortezomib monotherapy for relapsed multiple myeloma	Compliant	<a href="#">Multiple myeloma - bortezomib</a>
2007/10	TA130	Adalimumab, etanercept and infliximab for the treatment of	Not carried out at the	<a href="#">Rheumatoid arthritis - adalimumab, etanercept and infliximab</a>

		rheumatoid arthritis	Christie	
2007/09	TA111	Alzheimer's - donepezil, galantamine, rivastigmine (review) and memantine	Not carried out at the Christie	<a href="#">TA111 Alzheimer's - donepezil, galantamine, rivastigmine (review) and memantine: quick reference guide</a>
2007/09	TA128	Stapled haemorrhoidopexy for the treatment of haemorrhoids	Not carried out at the Christie	<a href="#">Haemorrhoid - stapled haemorrhoidopexy</a>
2007/08	TA126	Rituximab for the treatment of rheumatoid arthritis	Not carried out at the Christie	<a href="#">Rheumatoid arthritis (refractory) - rituximab</a>
2007/08	TA127	Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis	Not carried out at the Christie	<a href="#">Multiple sclerosis - natalizumab</a>
2007/08	TA124	Pemetrexed for the treatment of non-small-cell lung cancer	Compliant	<a href="#">Lung cancer (non-small cell) - pemetrexed</a>
2007/08	TA125	Adalimumab for the treatment of psoriatic arthritis	Not carried out at the Christie	<a href="#">Psoriatic arthritis (moderate to severe) - adalimumab</a>
2007/07	TA123	Varenicline for smoking cessation	Not carried out at the Christie	<a href="#">Smoking cessation - varenicline</a>
2007/06	TA122	Alteplase for the treatment of acute ischaemic stroke	Not carried out at the Christie	<a href="#">Ischaemic stroke (acute) - alteplase</a>
2007/06	TA121	Carmustine implants and temozolomide for the treatment of newly diagnosed	Compliant	<a href="#">Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide</a>

		high grade glioma		
2007/05	TA120	Cardiac resynchronisation therapy for the treatment of heart failure	Not carried out at the Christie	<a href="#">Heart failure - cardiac resynchronisation</a>
2007/02	TA119	Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia	Compliant	<a href="#">Leukaemia (lymphocytic) - fludarabine</a>
2007/01	TA115	Naltrexone for the management of opioid dependence	Not carried out at the Christie	<a href="#">Drug misuse - naltrexone</a>
2007/01	TA114	Methadone and buprenorphine for managing opioid dependence	Not carried out at the Christie	<a href="#">Drug misuse - methadone and buprenorphine</a>
2007/01	TA118	Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer	Compliant	<a href="#">Colorectal cancer (metastatic) - bevacizumab &amp; cetuximab</a>
2007/01	TA116	Gemcitabine for the treatment of metastatic breast cancer	Compliant	<a href="#">Breast cancer - gemcitabine</a>
2007/01	TA117	Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy	Not carried out at the Christie	<a href="#">Hyperparathyroidism - cinacalcet</a>
2006/12	TA113	Inhaled insulin for the treatment of type 1 and type 2 diabetes	Not carried out at the Christie	<a href="#">Diabetes (type 1 and 2) - inhaled insulin</a>

2006/11	TA112	Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer	Compliant	<a href="#">Breast cancer (early) - hormonal treatments</a>
2006/09	TA108	Paclitaxel for the adjuvant treatment of early node-positive breast cancer	Compliant	<a href="#">Breast cancer (early) - paclitaxel</a>
2006/09	TA109	Docetaxel for the adjuvant treatment of early node-positive breast cancer	Compliant	<a href="#">Breast cancer (early) - docetaxel</a>
2006/09	TA110	Rituximab for the treatment of follicular lymphoma	Compliant	<a href="#">Follicular lymphoma - rituximab</a>
2006/08	TA106	Hepatitis C - peginterferon alfa and ribavirin	Not carried out at the Christie	<a href="#">Hepatitis C - peginterferon alfa and ribavirin</a>
2006/08	TA107	Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer	Compliant	<a href="#">Breast cancer (early) - trastuzumab</a>
2006/08	TA105	Laparoscopic surgery for the treatment of colorectal cancer	Not carried out at the Christie	<a href="#">Colorectal cancer - laparoscopic surgery (review)</a>
2006/07	TA103	Etanercept and efalizumab for the treatment of adults with psoriasis	Not carried out at the Christie	<a href="#">Psoriasis - efalizumab and etanercept</a>
2006/07	TA104	Etanercept and infliximab for the	Not carried	<a href="#">Psoriatic arthritis - etanercept and infliximab</a>

		treatment of psoriatic arthritis	out at the Christie	
2006/07	TA102	Parent-training/education programmes in the management of children with conduct disorders	Not carried out at the Christie	<a href="#">Parent-training/education programmes in the management of children with conduct disorders</a>
2006/07	TA101	Docetaxel for the treatment of hormone refractory prostate cancer	Compliant	<a href="#">Prostate cancer (hormone-refractory) - docetaxel</a>
2006/05	TA99	Immunosuppressive therapy for renal transplantation in children and adolescents	Not carried out at the Christie	<a href="#">Renal transplantation - immunosuppressive regimens for children and adolescents (No. 99)</a>
2006/04	TA100	Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer	Compliant	<a href="http://nice.org.uk/download.aspx?o=TA100guidance">http://nice.org.uk/download.aspx?o=TA100guidance</a>
2006/03	TA98	Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (No. 98)	Not carried out at the Christie	<a href="#">Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (No. 98)</a>
2006/02	TA96	Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B	Not carried out at the Christie	<a href="http://www.nice.org.uk/pdf/TA096guidance.pdf">http://www.nice.org.uk/pdf/TA096guidance.pdf</a>
2006/02	TA97	Computerised cognitive behaviour therapy for depression and anxiety (Review	Not carried out at the Christie	<a href="http://www.nice.org.uk/pdf/TA097guidance.pdf">http://www.nice.org.uk/pdf/TA097guidance.pdf</a>

		of Technology Appraisal 51)		
2006/01	TA95	Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (no.95)	Not carried out at the Christie	<a href="#">Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (no.95)</a>
2005/08	TA93	Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review) (No. 93) (Review of TA 33)	Compliant	<a href="http://www.nice.org.uk/pdf/TA93Guidance.pdf">http://www.nice.org.uk/pdf/TA93Guidance.pdf</a>
2005/07	TA92	Tooth decay - HealOzone (No.92)	Not carried out at the Christie	<a href="http://www.nice.org.uk/pdf/TA092guidance.pdf">http://www.nice.org.uk/pdf/TA092guidance.pdf</a>
2005/05	TA91	Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (No. 91)	Compliant	<a href="#">Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer, a Review of Technology Appraisal Guidance 28, 45 and 55 - Guidance</a>
2004/10	TA86	Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours	Compliant	<a href="#">Gastro-intestinal stromal tumours (GIST) - imatinib</a>
2004/09	TA84	Drotrecogin alfa (activated) for severe sepsis	Not carried out at the Christie	<a href="#">TA084 Sepsis (severe) - drotrecogin - Guidance</a>
2003/10	TA70	Imatinib for chronic myeloid leukaemia	Compliant	<a href="#">Leukaemia (chronic myeloid) - imatinib (No. 70)</a>
2003/09	TA65	Rituximab for aggressive non-Hodgkin's	Compliant	<a href="#">Non-Hodgkin's lymphoma - rituximab (No. 65)</a>

		lymphoma		
2003/08	TA64	Human Growth Hormone (somatropin) in adults with growth hormone deficiency	Compliant	<a href="http://www.nice.org.uk/page.aspx?o=83406">http://www.nice.org.uk/page.aspx?o=83406</a>
2003/08	TA63	Glitazones for the treatment of type 2 diabetes	Not carried out at the Christie	<a href="#">Diabetes (type 2) - glitazones (review) (No. 63)</a>
2003/05	TA61	Use of Capecitabine and Tegafur with Uracil for metastatic colorectal cancer	Compliant	<a href="#">Colorectal cancer - capecitabine and tegafur uracil</a>
2003/04	TA53	Use of long-acting insulin analogues for the treatment of diabetes - insulin glargine	Not carried out at the Christie	<a href="#">Diabetes (types 1 and 2) - long acting insulin analogues (No. 53)</a>
2002/03	TA34	Trastuzumab for the treatment of advanced breast cancer	Compliant	<a href="#">Breast cancer - trastuzumab</a>
2001/09	TA49	Use of ultrasound locating devices for placing central venous catheters	Compliant	<a href="http://www.nice.org.uk/pdf/Ultrasound_49_GUIDANCE.pdf">http://www.nice.org.uk/pdf/Ultrasound_49_GUIDANCE.pdf</a>
2001/05	TA25	Gemcitabine for pancreatic cancer	Compliant	<a href="#">Pancreatic cancer - gemcitabine (No. 25)</a>
2001/04	TA23	Guidance on the use of Temozolamide for malignant glioma	Compliant	<a href="#">Brain cancer - temozolomide</a>
2000/05	TA01	Guidance on the removal of wisdom teeth	Compliant	<a href="#">Guidance on Removal of wisdom teeth</a>

	TA46	Use of surgery to aid weight reduction for people with morbid obesity	Not carried out at the Christie	
	TA52	Use of drugs for early thrombolysis in the treatment of acute myocardial infarction	Not carried out at the Christie	
	TA48	Home compared with hospital haemodialysis for patients with end-stage renal failure	Not carried out at the Christie	
	TA47	Use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes	Not carried out at the Christie	
	TA32	Beta-interferon and Glatiramer Acetate for the treatment of multiple sclerosis	Not carried out at the Christie	
	TA31	Guidance on the use of sibutramine for treatment of obesity in adults	Not carried out at the Christie	
	TA27	Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis	Not carried out at the Christie	

	TA22	Guidance on the use of Orlistat for the treatment of obesity in adults	Not carried out at the Christie	
	TA42	Human growth hormone (somatropin) in children with growth failure	Not carried out at the Christie	<a href="#">Growth hormone deficiency (children) - human growth hormone (No. 42)</a>
	TA20	Guidance on the use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease	Not carried out at the Christie	
	TA19	Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of alzheimer's disease	Not carried out at the Christie	
	TA16	Use of Autologous Cartilage Transplantation for Full Thickness Cartilage Defects in Knee Joints	Not carried out at the Christie	
	TA89	Cartilage injury - autologous chondrocyte implantation (ACI) (review) (No. 89)	Not carried out at the Christie	
	TA90	Vascular disease - clopidogrel and dipyridamole (No. 90)	Not carried out at the Christie	
	TA02	The selection of prostheses for primary total hip replacement	Not carried out at the Christie	
	TA72	Anakinra for	Not	

		rheumatoid arthritis	carried out at the Christie	
	TA83	Laparoscopic surgery for inguinal hernia repair	Not carried out at the Christie	
	TA81	Frequency of application of topical corticosteroids for atopic eczema	Not carried out at the Christie	
	TA80	Clopidogrel in the treatment of non-ST-segment-Elevation acute coronary syndrome	Not carried out at the Christie	
	TA79	Newer drugs for epilepsy in children	Not carried out at the Christie	
	TA77	Zaleplon, zolpidem and zopiclone for the short-term management of insomnia	Not carried out at the Christie	<a href="http://www.nice.org.uk/pdf/TA077fullguidance.pdf">http://www.nice.org.uk/pdf/TA077fullguidance.pdf</a>
	TA85	Immunosuppressive therapy for renal transplantation in adults	Not carried out at the Christie	
	TA82	Tacrolimus and pimecrolimus for atopic eczema	Not carried out at the Christie	
	TA78	Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual	Not carried out at the Christie	

		bleeding		
	TA76	Newer drugs for epilepsy in adults	Not carried out at the Christie	
	TA75	Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis-C	Not carried out at the Christie	
	TA40	Infliximab for Crohn's disease	Not carried out at the Christie	
	TA73	Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction	Not carried out at the Christie	
	TA35	Etanercept for the treatment of juvenile idiopathic arthritis	Not carried out at the Christie	
	TA69	Liquid-based cytology for cervical screening	Not carried out at the Christie	
	TA68	Photodynamic therapy for age-related macular degeneration	Not carried out at the Christie	
	TA66	Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar 1 disorder	Not carried out at the Christie	<a href="#">Bipolar disorder - new drugs (No. 66)</a>

	TA60	Use of patient-education models for diabetes	Not carried out at the Christie	<a href="#">Diabetes (types 1 and 2) - patient education models (No. 60)</a>
	TA59	Use of electroconvulsive therapy	Not carried out at the Christie	<a href="#">Electroconvulsive therapy (ECT) (No. 59)</a>
	TA56	Use of tension-free vaginal tape (Gynecare TVT) for stress incontinence	Not carried out at the Christie	<a href="#">Stress incontinence - tension-free vaginal tape (No. 56)</a>
	TA14	Guidance on the Use of Ribavirin and Interferon Alpha for Hepatitis C	Not carried out at the Christie	
	TA10	Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma	Not carried out at the Christie	
	TA44	Use of metal on metal hip resurfacing arthroplasty	Not carried out at the Christie	
	TA41	Routine antenatal anti-D prophylaxis for RhD-negative women	Not carried out at the Christie	
	TA38	Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years)	Not carried out at the Christie	
	TA74	Pre-hospital initiation of fluid replacement therapy in	Not carried out at the Christie	

		trauma		
--	--	--------	--	--